ribociclib
novartis
['bcsm', 'natalee', ' ribo', 'ribociclib']
natalee: adjuvant endocrine therapy + ribociclib 400 mg daily 3 wks on/1 off x 3 years. median follow-up 28 mo. 3.3% idfs benefit, 2.2% ddfs benefit. benefit across subgroups. os immature, trend to benefit. favorable safety profile.
#bcsm #asco23 dennis slamon of 
Medical oncologist @Intermountain, Director of Breast Oncology. Clinical research, quality improvement, cardio-oncology, provider wellness. All tweets my own.